- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Easton Pharmaceuticals Seeks to Get Herbs of Kedem
Easton Pharmaceuticals signed a letter of intent for the acquisition of Israeli therapeutics company Herbs of Kedem.
Easton Pharmaceuticals (OTC:EAPH) signed a letter of intent for the acquisition of Israeli therapeutics company Herbs of Kedem.
As quoted in the press release:
Herbs of Kedem is an Israeli based company with sales in excess of $2,200,000 US and healthy profit margins with a current net profit of approximately $1,500,000 US with minimal marketing exposure. Herbs of Kedem currently has a total of 10 adult skin care and anti-aging products, 5 hair care and hair loss products, 4 foot and nail care products, 16 skin care products, 6 respiratory tract treatment products and 4 food supplement products. Herbs of Kedem therapeutic natural products with its main ingredients being sourced from the Dead Sea and with distribution channels through many European and recently forged North American distributors, Easton believes the revenue capabilities of these products can grow exponentially as the quality is unmatched. Most of the products including its hair restoration product to treat male pattern baldness have undergone clinical trials. Easton expects to soon announce testing and sales trials of certain products in select stores at a Canadian Retail Pharmacy Chain, Shoppers Drug Mart, with over 1,253 locations in Canada. Additional updates on the proposed acquisition of Herbs Of Kadem will be announced as they become available.
Click here to read the full press release.
Source: www.marketwired.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.